Search results
-
Daiichi ups its Glycotope bet
… None Ph1 in Claudin6+ve solid tumours; initial data at ESMO 2024: Source: OncologyPipeline. …
- 01/16/2025 - 13:06 -
I-Mab bets on a Bristol buy-in
… Givastomig Claudin18.2 x 4-1BB Ph1 monoRx data at ESMO 2024; Opdivo + chemo combo data (BMS clinical trial …
- 01/07/2025 - 15:45 -
The month ahead: January’s upcoming events
… dosing in Jul 2024; 8 treatment-related deaths reported at ESMO 2024 Source: OncologyPipeline. …
- 01/02/2025 - 17:41 -
Cabometyx’s Cabinet committee
… 3 April PDUFA date. Source: Dr Jennifer Chan & ESMO 2024. Regulatory …
- 11/28/2024 - 14:33 -
Amgen pushes on in Steap1
… therapy. In phase 1 dose-expansion cohorts, presented at ESMO 2024, xaluritamig produced an ORR of 29% with the …
- 11/21/2024 - 16:15 -
Not so fast for Astra in bladder cancer
… Imfinzi (adjuvant), vs chemo Positive data presented at ESMO 2024; filed in EU (decision expected in H2 2025); as of …
- 11/14/2024 - 14:46 -
Triple meeting 2024 – Revolution shows selective KRAS promise
… (solid tumours) Venue Triple meeting 2024 ESMO 2024 ORR 30% (12/40)* 19% (5/27)** …
- 03/26/2025 - 09:29 -
Another hold for BioNTech
… & 2mg/kg Q3W (reduced from 3 & 6mg/kg Q3W) Data at ESMO 2024: ORR 25-28%, Gr≥3 TRAEs 41-46%, discontinuation …
- 10/22/2024 - 13:40 -
Transgene stumbles with its fixed immunotherapy
… in relapsed solid tumours +/- Keytruda Data at ESMO 2024: 2/6 responses with Keytruda combo TG6050 …
- 10/15/2024 - 14:26 -
J&J’s Sunrise dims
… BCG unresponsive +/- cetrelimab vs cetrelimab Data at ESMO 2024: CR 84% vs 46% with TAR-200 mono vs cetrelimab; … cystectomy + cetrelimab vs cetrelimab Data at ESMO 2024: pCR 42% vs 23% with TAR-200 + cetrelimab vs …
- 10/10/2024 - 13:12
